Cargando…

Circulating Cytokines and Growth Factors in Acute Cerebral Large Vessel Occlusion—Association with Success of Endovascular Treatment

Mechanical thrombectomy (MT) is a highly efficient treatment in patients with acute ischemic stroke due to large vessel occlusion (LVO). However, in a relevant proportion of LVO, no sufficient recanalization can be achieved. The composition of cerebral thrombi is highly heterogeneous and may constit...

Descripción completa

Detalles Bibliográficos
Autores principales: Grosse, Gerrit M., Werlein, Christopher, Blume, Nicole, Abu-Fares, Omar, Götz, Friedrich, Gabriel, Maria M., Ernst, Johanna, Leotescu, Andrei, Worthmann, Hans, Kühnel, Mark P., Jonigk, Danny D., Falk, Christine S., Weissenborn, Karin, Schuppner, Ramona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142215/
https://www.ncbi.nlm.nih.gov/pubmed/34225367
http://dx.doi.org/10.1055/a-1544-5431
_version_ 1784715523276144640
author Grosse, Gerrit M.
Werlein, Christopher
Blume, Nicole
Abu-Fares, Omar
Götz, Friedrich
Gabriel, Maria M.
Ernst, Johanna
Leotescu, Andrei
Worthmann, Hans
Kühnel, Mark P.
Jonigk, Danny D.
Falk, Christine S.
Weissenborn, Karin
Schuppner, Ramona
author_facet Grosse, Gerrit M.
Werlein, Christopher
Blume, Nicole
Abu-Fares, Omar
Götz, Friedrich
Gabriel, Maria M.
Ernst, Johanna
Leotescu, Andrei
Worthmann, Hans
Kühnel, Mark P.
Jonigk, Danny D.
Falk, Christine S.
Weissenborn, Karin
Schuppner, Ramona
author_sort Grosse, Gerrit M.
collection PubMed
description Mechanical thrombectomy (MT) is a highly efficient treatment in patients with acute ischemic stroke due to large vessel occlusion (LVO). However, in a relevant proportion of LVO, no sufficient recanalization can be achieved. The composition of cerebral thrombi is highly heterogeneous and may constitute a relevant factor for insufficient reperfusion. We hypothesized that circulating cytokines and growth factors involved in thromboinflammation and platelet activation may be associated with reperfusion status and thrombus composition in patients undergoing MT. An according biomarker panel was measured in plasma specimens taken prior to MT and at a 7-day follow-up. The reperfusion status was categorized into sufficient or insufficient. The composition of retrieved thrombi was histologically analyzed. Differences of baseline biomarker concentrations between insufficient and sufficient reperfusions were highest for interferon (IFN)-γ, epidermal growth factor, platelet-derived growth factor (PDGF)-AB/BB, and IFN-γ-induced protein 10 (IP-10/CXCL10). After applying correction for multiple comparisons and logistic regression analysis adjusting for stroke etiology, intravenous thrombolysis, and vascular risk factors, PDGF-AB/BB was identified as an independent predictor of reperfusion status (odds ratio: 0.403; 95% confidence interval: 0.199–0.819). Histological analysis revealed that the majority of thrombi had a mixed composition. In conclusion, this study provides the first evidence that cytokines and growth factors are potential effectors in patients undergoing MT for the treatment of acute ischemic stroke.
format Online
Article
Text
id pubmed-9142215
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-91422152022-05-28 Circulating Cytokines and Growth Factors in Acute Cerebral Large Vessel Occlusion—Association with Success of Endovascular Treatment Grosse, Gerrit M. Werlein, Christopher Blume, Nicole Abu-Fares, Omar Götz, Friedrich Gabriel, Maria M. Ernst, Johanna Leotescu, Andrei Worthmann, Hans Kühnel, Mark P. Jonigk, Danny D. Falk, Christine S. Weissenborn, Karin Schuppner, Ramona Thromb Haemost Mechanical thrombectomy (MT) is a highly efficient treatment in patients with acute ischemic stroke due to large vessel occlusion (LVO). However, in a relevant proportion of LVO, no sufficient recanalization can be achieved. The composition of cerebral thrombi is highly heterogeneous and may constitute a relevant factor for insufficient reperfusion. We hypothesized that circulating cytokines and growth factors involved in thromboinflammation and platelet activation may be associated with reperfusion status and thrombus composition in patients undergoing MT. An according biomarker panel was measured in plasma specimens taken prior to MT and at a 7-day follow-up. The reperfusion status was categorized into sufficient or insufficient. The composition of retrieved thrombi was histologically analyzed. Differences of baseline biomarker concentrations between insufficient and sufficient reperfusions were highest for interferon (IFN)-γ, epidermal growth factor, platelet-derived growth factor (PDGF)-AB/BB, and IFN-γ-induced protein 10 (IP-10/CXCL10). After applying correction for multiple comparisons and logistic regression analysis adjusting for stroke etiology, intravenous thrombolysis, and vascular risk factors, PDGF-AB/BB was identified as an independent predictor of reperfusion status (odds ratio: 0.403; 95% confidence interval: 0.199–0.819). Histological analysis revealed that the majority of thrombi had a mixed composition. In conclusion, this study provides the first evidence that cytokines and growth factors are potential effectors in patients undergoing MT for the treatment of acute ischemic stroke. Georg Thieme Verlag KG 2021-07-05 /pmc/articles/PMC9142215/ /pubmed/34225367 http://dx.doi.org/10.1055/a-1544-5431 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Grosse, Gerrit M.
Werlein, Christopher
Blume, Nicole
Abu-Fares, Omar
Götz, Friedrich
Gabriel, Maria M.
Ernst, Johanna
Leotescu, Andrei
Worthmann, Hans
Kühnel, Mark P.
Jonigk, Danny D.
Falk, Christine S.
Weissenborn, Karin
Schuppner, Ramona
Circulating Cytokines and Growth Factors in Acute Cerebral Large Vessel Occlusion—Association with Success of Endovascular Treatment
title Circulating Cytokines and Growth Factors in Acute Cerebral Large Vessel Occlusion—Association with Success of Endovascular Treatment
title_full Circulating Cytokines and Growth Factors in Acute Cerebral Large Vessel Occlusion—Association with Success of Endovascular Treatment
title_fullStr Circulating Cytokines and Growth Factors in Acute Cerebral Large Vessel Occlusion—Association with Success of Endovascular Treatment
title_full_unstemmed Circulating Cytokines and Growth Factors in Acute Cerebral Large Vessel Occlusion—Association with Success of Endovascular Treatment
title_short Circulating Cytokines and Growth Factors in Acute Cerebral Large Vessel Occlusion—Association with Success of Endovascular Treatment
title_sort circulating cytokines and growth factors in acute cerebral large vessel occlusion—association with success of endovascular treatment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142215/
https://www.ncbi.nlm.nih.gov/pubmed/34225367
http://dx.doi.org/10.1055/a-1544-5431
work_keys_str_mv AT grossegerritm circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment
AT werleinchristopher circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment
AT blumenicole circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment
AT abufaresomar circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment
AT gotzfriedrich circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment
AT gabrielmariam circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment
AT ernstjohanna circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment
AT leotescuandrei circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment
AT worthmannhans circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment
AT kuhnelmarkp circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment
AT jonigkdannyd circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment
AT falkchristines circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment
AT weissenbornkarin circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment
AT schuppnerramona circulatingcytokinesandgrowthfactorsinacutecerebrallargevesselocclusionassociationwithsuccessofendovasculartreatment